<p>Squarepoint Ops LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第二季度将其在 Cytokinetics, Incorporated (NASDAQ:CYTK - 免费报告) 的持仓削减了 82.3%。该公司在季度内出售了 85,480 股后，持有该生物制药公司 18,398 股股票。Squarepoint Ops LLC 在 Cytokinetics 的持股在最近一个季度末价值 608,000 美元。</p>
<ul>
<li>分析师认为仍有机会投资 Edgewise，股价上涨 332%</li>
</ul>
<p>其他机构投资者也对该公司的持仓进行了调整。HighTower Advisors LLC 在第一季度将其在 Cytokinetics 的股份增加了 21.8%。HighTower Advisors LLC 目前持有 11,352 股该生物制药公司的股票，价值 456,000 美元，此前在上个季度增持了 2,029 股。CW Advisors LLC 在第一季度获得了 Cytokinetics 的新股份，价值 1,125,000 美元。AlphaQuest LLC 在第一季度将其在 Cytokinetics 的持股增加了 485.4%。AlphaQuest LLC 目前持有 6,650 股该生物制药公司的股票，价值 267,000 美元，此前在上个季度增持了 5,514 股。Comerica Bank 在第一季度将其在 Cytokinetics 的持仓增加了 3.2%。Comerica Bank 目前持有 243,109 股该生物制药公司的股票，价值 9,771,000 美元，此前在此期间增持了 7,645 股。最后，Gabelli Funds LLC 在第一季度将其在 Cytokinetics 的持仓增加了 30.0%。Gabelli Funds LLC 目前持有 6,500 股该生物制药公司的股票，价值 261,000 美元，此前在此期间增持了 1,500 股。</p>
<h2>Cytokinetics 股票表现</h2>
<p>NASDAQ:CYTK 周三开盘价为 63.29 美元。该公司的市值为 77.4 亿美元，市盈率为 -10.06，贝塔值为 0.58。该股票的 50 日移动平均价格为 62.87 美元，200 日移动平均价格为 49.10 美元。Cytokinetics, Incorporated 的 52 周低点为 29.31 美元，52 周高点为 70.98 美元。</p>
<ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
<p>Cytokinetics (NASDAQ:CYTK - 获取免费报告) 最近在 11 月 5 日发布了其财报。该生物制药公司报告本季度每股收益为（$1.54），超出市场共识预期的（$1.59）0.05 美元。该公司在本季度的收入为 194 万美元，而市场共识预期为 605 万美元。该公司的收入同比增长 318.1%。在去年同期，该公司每股收益为（$1.36）。整体来看，卖方分析师预测 Cytokinetics, Incorporated 本财年的每股收益将为 -5.24。</p>
<h2>关于 Cytokinetics 的热门头条</h2>
<p>以下是本周影响 Cytokinetics 的主要新闻：</p>
<ul>
<li>积极情绪：FDA 批准 Myqorzo（aficamten）用于阻塞性肥厚型心肌病，使 Cytokinetics 成为一家商业阶段的心脏病生物技术公司，并开启新的收入增长通道——这是推动股价上涨的主要因素。文章标题</li>
<li>积极情绪：多家券商提高了目标价并重申买入/跑赢大盘的观点（巴克莱、摩根士丹利、美银、尼德汉、Citizens/JMP），表明分析师对商业前景的信心增强，支持股价上涨。文章标题</li>
<li>积极情绪：异常大量的看涨期权买入（约 5,619 份看涨期权，约 103% 超过典型日交易量）表明交易者正在为额外的上涨或近期的看涨走势进行布局。（期权交易量报告）</li>
<li>积极情绪：分析师评论强调 MYQORZO 相较于现有产品的实际标签优势（灵活剂量），管理层目标是实现显著的市场份额增长——这一评论支持了多季度的采用故事。文章标题</li>
<li>中性情绪：Citizens 维持对 CYTK 的市场跑赢评级，虽然支持但并不是新的认可。文章标题</li>
<li>消极情绪：内部人士出售：董事 Wendell Wierenga 以平均 66.14 美元的价格出售了 20,000 股，削减其持股约 38%——这可能对一些投资者构成短期阻力或警示信号。SEC 文件</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<p>几位研究分析师最近对该公司发表了看法。HC Wainwright 将 Cytokinetics 的目标价从 120.00 美元上调至 136.00 美元，并在周一的研究报告中给予该公司 “买入” 评级。高盛集团在 12 月 18 日的报告中将 Cytokinetics 的目标价设定为 95.00 美元，并给予该公司 “买入” 评级。花旗集团在周一的报告中重申了对 Cytokinetics 股票的 “市场跑赢” 评级。Cantor Fitzgerald 在 10 月 21 日的研究报告中重申了对 Cytokinetics 股票的 “增持” 评级。最后，加拿大皇家银行在周一的研究报告中将 Cytokinetics 股票的目标价从 87.00 美元上调至 95.00 美元，并给予该股票 “跑赢大盘” 评级。十五位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 83.61 美元。</p>
<p><strong>查看我们最新的 Cytokinetics 股票分析</strong></p>
<h2>Cytokinetics 的内部交易</h2>
<p>在相关消息中，董事 Wendell Wierenga 于 12 月 22 日星期一出售了 20,000 股公司的股票。该股票的平均售价为 66.14 美元，总价值为 1,322,800.00 美元。交易后，该董事直接持有 32,444 股公司的股票，估值约为 2,145,846.16 美元。这笔交易代表其持股减少了 38.14%。该出售在向证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，董事 Edward M. Md Kaye 于 12 月 1 日星期一出售了 28,064 股公司的股票。该股票的平均售价为 66.72 美元，总价值为 1,872,430.08 美元。出售完成后，该董事持有 9,977 股公司的股票，估值约为 665,665.44 美元。这笔交易代表其持股减少了 73.77%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 168,494 股公司股票，价值为 10,811,018 美元。目前，3.40% 的股票由公司内部人士持有。</p>
<h2>关于细胞动力</h2>
<p>(免费报告)</p>
<p>细胞动力公司是一家处于后期阶段的生物制药公司，专注于发现和开发调节肌肉功能的新型小分子治疗药物。公司成立于 1998 年，总部位于加利福尼亚州南旧金山，利用其在肌肉生物学方面的专有见解，解决肌肉功能受损所致的疾病。其研究涵盖心脏和骨骼肌靶点，旨在为具有显著未满足医疗需求的疾病提供创新药物。</p>
<p>该公司的最先进项目 omecamtiv mecarbil 正在评估用于通过增强心脏肌肉收缩力来治疗心力衰竭。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过细胞动力</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解读</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于细胞动力吗？</h2>
<p>在考虑细胞动力之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而细胞动力并不在名单上。</p>
<p>虽然细胞动力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

细胞动力

<p>Squarepoint Ops LLC 在第二季度将其在细胞动力的股份减少了 82.3%，持有价值 608,000 美元的股票。其他投资者调整了他们的持仓，其中一些增加了他们的持股。细胞动力的股票开盘价为 63.29 美元，市值为 77.4 亿美元。分析师提高了目标价格，FDA 批准了 Myqorzo，提升了前景。然而，一位董事的内部出售可能在短期内引发担忧</p>

<p>Squarepoint Ops LLC trimmed its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 82.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,398 shares of the biopharmaceutical company's stock after selling 85,480 shares during the quarter. Squarepoint Ops LLC's holdings in Cytokinetics were worth $608,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Squarepoint Ops LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第二季度将其在 Cytokinetics, Incorporated (NASDAQ:CYTK - 免费报告) 的持仓削减了 82.3%。该公司在季度内出售了 85,480 股后，持有该生物制药公司 18,398 股股票。Squarepoint Ops LLC 在 Cytokinetics 的持股在最近一个季度末价值 608,000 美元。</p>
</div><ul>
<li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为仍有机会投资 Edgewise，股价上涨 332%</li>
</ul>
</div><p>Other institutional investors have also made changes to their positions in the company. HighTower Advisors LLC lifted its position in shares of Cytokinetics by 21.8% in the 1st quarter. HighTower Advisors LLC now owns 11,352 shares of the biopharmaceutical company's stock valued at $456,000 after acquiring an additional 2,029 shares in the last quarter. CW Advisors LLC acquired a new stake in Cytokinetics during the 1st quarter valued at $1,125,000. AlphaQuest LLC lifted its holdings in shares of Cytokinetics by 485.4% in the first quarter. AlphaQuest LLC now owns 6,650 shares of the biopharmaceutical company's stock valued at $267,000 after purchasing an additional 5,514 shares in the last quarter. Comerica Bank boosted its position in shares of Cytokinetics by 3.2% in the first quarter. Comerica Bank now owns 243,109 shares of the biopharmaceutical company's stock worth $9,771,000 after buying an additional 7,645 shares during the period. Finally, Gabelli Funds LLC boosted its position in shares of Cytokinetics by 30.0% in the first quarter. Gabelli Funds LLC now owns 6,500 shares of the biopharmaceutical company's stock worth $261,000 after buying an additional 1,500 shares during the period.</p>
<div class="lb-trans"><p>其他机构投资者也对该公司的持仓进行了调整。HighTower Advisors LLC 在第一季度将其在 Cytokinetics 的股份增加了 21.8%。HighTower Advisors LLC 目前持有 11,352 股该生物制药公司的股票，价值 456,000 美元，此前在上个季度增持了 2,029 股。CW Advisors LLC 在第一季度获得了 Cytokinetics 的新股份，价值 1,125,000 美元。AlphaQuest LLC 在第一季度将其在 Cytokinetics 的持股增加了 485.4%。AlphaQuest LLC 目前持有 6,650 股该生物制药公司的股票，价值 267,000 美元，此前在上个季度增持了 5,514 股。Comerica Bank 在第一季度将其在 Cytokinetics 的持仓增加了 3.2%。Comerica Bank 目前持有 243,109 股该生物制药公司的股票，价值 9,771,000 美元，此前在此期间增持了 7,645 股。最后，Gabelli Funds LLC 在第一季度将其在 Cytokinetics 的持仓增加了 30.0%。Gabelli Funds LLC 目前持有 6,500 股该生物制药公司的股票，价值 261,000 美元，此前在此期间增持了 1,500 股。</p>
</div><h2>Cytokinetics Stock Performance</h2>
<div class="lb-trans"><h2>Cytokinetics 股票表现</h2>
</div><p>NASDAQ:CYTK opened at $63.29 on Wednesday. The company has a market capitalization of $7.74 billion, a P/E ratio of -10.06 and a beta of 0.58. The stock's 50 day moving average price is $62.87 and its 200 day moving average price is $49.10. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $70.98.</p>
<div class="lb-trans"><p>NASDAQ:CYTK 周三开盘价为 63.29 美元。该公司的市值为 77.4 亿美元，市盈率为 -10.06，贝塔值为 0.58。该股票的 50 日移动平均价格为 62.87 美元，200 日移动平均价格为 49.10 美元。Cytokinetics, Incorporated 的 52 周低点为 29.31 美元，52 周高点为 70.98 美元。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
</div><p>Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The business had revenue of $1.94 million during the quarter, compared to the consensus estimate of $6.05 million. The business's revenue was up 318.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.36) earnings per share. As a group, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cytokinetics (NASDAQ:CYTK - 获取免费报告) 最近在 11 月 5 日发布了其财报。该生物制药公司报告本季度每股收益为（$1.54），超出市场共识预期的（$1.59）0.05 美元。该公司在本季度的收入为 194 万美元，而市场共识预期为 605 万美元。该公司的收入同比增长 318.1%。在去年同期，该公司每股收益为（$1.36）。整体来看，卖方分析师预测 Cytokinetics, Incorporated 本财年的每股收益将为 -5.24。</p>
</div><h2>Trending Headlines about Cytokinetics</h2>
<div class="lb-trans"><h2>关于 Cytokinetics 的热门头条</h2>
</div><p>Here are the key news stories impacting Cytokinetics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Cytokinetics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: FDA approved Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, turning Cytokinetics into a commercial-stage cardiology biotech and opening a new revenue runway — a primary driver behind the rally. Article Title</li>
<li>Positive Sentiment: Multiple brokers lifted price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, BofA, Needham, Citizens/JMP), signaling stronger analyst conviction on commercial prospects and supporting upside. Article Title</li>
<li>Positive Sentiment: Unusually heavy call-option buying (about 5,619 calls, ~103% above typical daily volume) suggests traders are positioning for additional upside or near-term bullish moves. (Options volume report)</li>
<li>Positive Sentiment: Analyst commentary highlights practical label advantages for MYQORZO vs. the incumbent (flexible dosing), and management targets substantial market share gains — commentary that supports a multi-quarter adoption story. Article Title</li>
<li>Neutral Sentiment: Citizens maintained its Market Outperform rating on CYTK, which is supportive but not a new endorsement. Article Title</li>
<li>Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at an average $66.14 (Dec. 22), trimming his stake ~38% — a potential short-term headwind or cautionary signal for some investors. SEC Filing</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：FDA 批准 Myqorzo（aficamten）用于阻塞性肥厚型心肌病，使 Cytokinetics 成为一家商业阶段的心脏病生物技术公司，并开启新的收入增长通道——这是推动股价上涨的主要因素。文章标题</li>
<li>积极情绪：多家券商提高了目标价并重申买入/跑赢大盘的观点（巴克莱、摩根士丹利、美银、尼德汉、Citizens/JMP），表明分析师对商业前景的信心增强，支持股价上涨。文章标题</li>
<li>积极情绪：异常大量的看涨期权买入（约 5,619 份看涨期权，约 103% 超过典型日交易量）表明交易者正在为额外的上涨或近期的看涨走势进行布局。（期权交易量报告）</li>
<li>积极情绪：分析师评论强调 MYQORZO 相较于现有产品的实际标签优势（灵活剂量），管理层目标是实现显著的市场份额增长——这一评论支持了多季度的采用故事。文章标题</li>
<li>中性情绪：Citizens 维持对 CYTK 的市场跑赢评级，虽然支持但并不是新的认可。文章标题</li>
<li>消极情绪：内部人士出售：董事 Wendell Wierenga 以平均 66.14 美元的价格出售了 20,000 股，削减其持股约 38%——这可能对一些投资者构成短期阻力或警示信号。SEC 文件</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research analysts recently weighed in on the company. HC Wainwright upped their price target on Cytokinetics from $120.00 to $136.00 and gave the company a &#34;buy&#34; rating in a research report on Monday. The Goldman Sachs Group set a $95.00 target price on Cytokinetics and gave the company a &#34;buy&#34; rating in a report on Thursday, December 18th. Citigroup restated a &#34;market outperform&#34; rating on shares of Cytokinetics in a report on Monday. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Cytokinetics in a research report on Tuesday, October 21st. Finally, Royal Bank Of Canada increased their target price on shares of Cytokinetics from $87.00 to $95.00 and gave the stock an &#34;outperform&#34; rating in a research report on Monday. Fifteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $83.61.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司发表了看法。HC Wainwright 将 Cytokinetics 的目标价从 120.00 美元上调至 136.00 美元，并在周一的研究报告中给予该公司 “买入” 评级。高盛集团在 12 月 18 日的报告中将 Cytokinetics 的目标价设定为 95.00 美元，并给予该公司 “买入” 评级。花旗集团在周一的报告中重申了对 Cytokinetics 股票的 “市场跑赢” 评级。Cantor Fitzgerald 在 10 月 21 日的研究报告中重申了对 Cytokinetics 股票的 “增持” 评级。最后，加拿大皇家银行在周一的研究报告中将 Cytokinetics 股票的目标价从 87.00 美元上调至 95.00 美元，并给予该股票 “跑赢大盘” 评级。十五位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 83.61 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Cytokinetics</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Cytokinetics 股票分析</strong></p>
</div><h2>Insider Transactions at Cytokinetics</h2>
<div class="lb-trans"><h2>Cytokinetics 的内部交易</h2>
</div><p>In related news, Director Wendell Wierenga sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the transaction, the director directly owned 32,444 shares of the company's stock, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, Director Edward M. Md Kaye sold 28,064 shares of the business's stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $66.72, for a total value of $1,872,430.08. Following the completion of the sale, the director owned 9,977 shares of the company's stock, valued at approximately $665,665.44. This trade represents a 73.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 168,494 shares of company stock valued at $10,811,018 in the last three months. 3.40% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Wendell Wierenga 于 12 月 22 日星期一出售了 20,000 股公司的股票。该股票的平均售价为 66.14 美元，总价值为 1,322,800.00 美元。交易后，该董事直接持有 32,444 股公司的股票，估值约为 2,145,846.16 美元。这笔交易代表其持股减少了 38.14%。该出售在向证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，董事 Edward M. Md Kaye 于 12 月 1 日星期一出售了 28,064 股公司的股票。该股票的平均售价为 66.72 美元，总价值为 1,872,430.08 美元。出售完成后，该董事持有 9,977 股公司的股票，估值约为 665,665.44 美元。这笔交易代表其持股减少了 73.77%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 168,494 股公司股票，价值为 10,811,018 美元。目前，3.40% 的股票由公司内部人士持有。</p>
</div><h2>About Cytokinetics</h2>
<div class="lb-trans"><h2>关于细胞动力</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.</p>
<div class="lb-trans"><p>细胞动力公司是一家处于后期阶段的生物制药公司，专注于发现和开发调节肌肉功能的新型小分子治疗药物。公司成立于 1998 年，总部位于加利福尼亚州南旧金山，利用其在肌肉生物学方面的专有见解，解决肌肉功能受损所致的疾病。其研究涵盖心脏和骨骼肌靶点，旨在为具有显著未满足医疗需求的疾病提供创新药物。</p>
</div><p>The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.</p>
<div class="lb-trans"><p>该公司的最先进项目 omecamtiv mecarbil 正在评估用于通过增强心脏肌肉收缩力来治疗心力衰竭。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cytokinetics</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump Did WHAT??</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过细胞动力</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解读</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CYTK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytokinetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于细胞动力吗？</h2>
</div><p>Before you consider Cytokinetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑细胞动力之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而细胞动力并不在名单上。</p>
</div><p>While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然细胞动力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Squarepoint Ops LLC 在 Cytokinetics, Incorporated 中持有价值 608,000 美元的股份